1. Germany Stocks

  2. •

    Health technology

  3. •

    Medical specialties
aap Implantate AG

aap Implantate AG

1.45
EUR
-0.11
(-7.05%)
-2.60EPS
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
8.16
4.31
3.62
3.08
3.44
3.46
3.66
2.68
2.48
1.93
1.38
1.19
0.9
3.48
Basic EPS, GAAP
-0.6
-0.13
-1.56
-2.72
-2.93
-2.46
-6.09
-2.54
-0.55
-0.43
-0.96
-0.35
-0.19
-2.61
Free Cash Flow per Basic Share
1.05
-0.85
-0.67
-2.11
-2.14
-2.85
-2.32
-1.18
-0.61
-0.4
-0.4
-0.14
-0.16
-2.41
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
13.87
13.4
11.89
16.07
13.44
11
5.42
2.96
2.57
1.95
0.9
0.77
0.63
9.75
Tangible Book Value per Share
9.6
8.91
8.81
12.8
9.7
6.82
4.51
2.22
2.1
1.63
0.68
0.63
0.48
5.79
Basic Weighted Avg Shares
3
3
3
3
3
3
3
3
5
6
8
10
14
3
Sales/Revenue/Turnover
28
15
12
10
11
11
12
9
12
12
11
12
12
11
Operating Margin (%)
7.79
-43.39
-70.67
-94.2
-73.68
-75.82
-63.77
-81.42
-22.12
-29.42
-61.46
-22.27
-20.4
-75.34
Depreciation Expense
9
2
3
2
2
2
13
3
2
2
4
2
2
2
Net Income, GAAP
-2
- -
-5
-9
-9
-8
-20
-9
-3
-3
-8
-4
-3
-8
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-7.4
-3.12
-43.09
-88.39
-85.04
-71.11
-166.28
-94.6
-22.18
-22.26
-69.38
-29.75
-20.7
-74.82
Working Capital
29
25
25
36
24
15
9
6
7
6
3
4
4
15
LT Debt
2
2
1
1
1
- -
2
3
3
1
3
- -
1
- -
Total Equity
47
45
40
55
43
35
19
10
13
13
8
10
9
34
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-4.26
-0.99
-12.34
-19.5
-19.05
-19.79
-72.58
-60.51
-23.4
-20.03
-76.1
-39.11
-26.99
-23.25

Capital Structure

EUR

•

in mil. unless spec.
Dec'18
Mar'19
Jun'19
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
- -
- -
- -

Working Capital

EUR

•

in mil. unless spec.
Dec'18
Mar'19
Jun'19
Total Current Assets
20
17
20
Cash, Cash Equivalents & STI
7
6
8
Accounts Receivable, Net
3
3
2
Inventories
10
9
9
Total Current Liabilities
5
4
5
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-9.58%
-0.01%
-16.89%
Free Cash Flow
16.65%
-3.08%
48.49%
Net Income, GAAP
21.07%
10.59%
-28.79%
Sales/Revenue/Turnover
1%
6.69%
2.33%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
12
2025
- -
- -
12
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.35
2025
- -
- -
-0.19
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Rubino di Girolamo
Full Time Employees
99
Sector
Health technology
Industry
Medical specialties
Address
Lorenzweg 5 Berlin BE Germany 12099
IPO Date
May 10, 1999
Website
aap.de
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
aap Implantate AG develops, manufactures and markets innovative trauma implants and biomaterials for orthopedics, focusing on the ortho/trauma/spine segment; its core IP-protected portfolio centers on the LOQTEQ anatomical plating system incorporating proprietary locking-compression technology, a comprehensive range of cannulated screws including the HBS screw system, standard plates and screws, and an innovation pipeline featuring antibacterial silver coating technology and resorbierbare magnesium-based implants addressing unmet needs such as infection risk reduction and avoidance of secondary surgeries. Founded in 1990 and headquartered in Berlin, Germany, the company operates globally through direct sales in Germany to hospitals and purchasing groups, a hybrid distribution strategy in the US via its subsidiary aap Implants Inc. in Dover, Delaware, and a network of distributors in around 25 countries across EMEA (52% of sales including strong growth in Spain/Portugal and South Africa), LATAM (Mexico, Brazil, Chile, Peru), and APAC (Thailand, Taiwan, Malaysia, South Korea); wholly-owned subsidiaries include MCTeQ GmbH and MAGIC Implants GmbH in Berlin, with a minority stake in AEQUOS Endoprothetik GmbH. Recent developments include successful completion of a BMBF-funded human clinical trial for its antibacterial silver coating technology in August 2025 with approvals targeted for CE-MDR, FDA and China from 2028, achievement of MDR certification and first product files strengthening European market access, US FDA approval for the HBS screw system, implementation of a January 2024 distribution agreement with a leading global spine and orthopedics company launching LOQTEQ VA Radius System sales in France, multiple equity measures such as cash and non-cash capital increases totaling around EUR 2.6 million in 2024 to boost equity to 66% of total assets and reduce interest-bearing liabilities to EUR 233 thousand, strong sales growth of 15% in Q3 2025 and 6% for FY 2024 to EUR 12.2 million driven by EMEA (+16%), LATAM (+22%) and APAC (+43% in Thailand), extension of CEO Rubino Di Girolamo's contract through 2028, and full admission of all shares to stock exchange trading under ISIN DE000A3H2101 from August 2025 eliminating prior lock-ups.